alexa Utility of Ultrasound vs. Gene Expression Classifier in Thyroid Nodules with Atypia of Undetermined Significance

ISSN: 2476-2253

Journal of Cancer Diagnosis

  • Research Article   
  • J Cancer Diagn 2016, Vol 1(1): 103
  • DOI: 10.4172/2476-2253.1000103

Utility of Ultrasound vs. Gene Expression Classifier in Thyroid Nodules with Atypia of Undetermined Significance

Carmen V Villabona1*, Vineeth Mohan1, Karla M Arce2, Julia Diacovo3, Alisha Aggarwal1, Jessica Betancourt4, Hassan Amer1, Pascual DeSantis1, Jose Cabral1 and Tessey Jose1
1Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, Florida, USA
2Department of Endocrinology, Cleveland Clinic Ohio, 9500 Euclid Avenue, Cleveland, Ohio, USA
3Department of Pathology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, Florida, USA
4Department of Internal Medicine, Lincoln Medical and Mental Health Center, NewYork, USA
*Corresponding Author: Carmen V Villabona MD, Cleveland Clinic Ohio, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, Florida, 33331, USA, Tel: 3123074488, Email: [email protected]

Received Date: Jan 18, 2016 / Accepted Date: Jan 30, 2016 / Published Date: Feb 06, 2016

Abstract

Introduction: Thyroid nodules with fine needle aspiration (FNA) cytology categorized as atypia of undetermined significance (AUS) often undergo additional diagnostic analysis with the Afirma Gene Expression Classifier (GEC) which classifies these as either high probability of being benign (GEC-B) or suspicious for malignancy (GEC-S). Our goal was to assess the clinical validity and utility of GEC in the evaluation of AUS cytology and evaluate the performance of ultrasonography (USG) for predicting malignancy in this subset.

Methods: We conducted a study with a retrospective cohort of patients from January 2012- January 2014 who had FNA of thyroid nodules >1 cm in size with AUS cytology.

Results: Cleveland Clinic Florida has an overall incidence of AUS of 5%. 119 cases with nodules >1 cm in size were reported as AUS. 48 (40.3%) had a GEC performed after the first FNA (AUS-1) and 27 of these were GEC-S. Of those 27, 21 went for surgery and 14 (66.6%) had thyroid cancer on histopathology. The remaining 71 with AUS-1 were sent for a 2nd FNA:19 nodules were benign and did not undergo further evaluation while the remaining 52 were reported as AUS for the second consecutive time (AUS-2). AUS-2 samples were sent for GEC. Of these 52 AUS-2, 38 (73.1%) were reported as GEC-S. 35 went for surgery and 32 (91.4%) had confirmed malignancy on histopathology. Positive Predictive Value (PPV) was 91.4% for AUS-2 vs. 66.6% for AUS -1. Moreover, AUS-2 nodules that were hypoechoic and solid on USG showed a PPV of 92% for malignancy.

Conclusion: In our practice, the diagnostic accuracy to predict malignancy with GEC for AUS-1 nodules was poor (PPV 66.6%). The PPV of GEC testing was markedly higher at 91.4% performed after 2 consecutive AUS cytologies. AUS-2 nodules that were solid and hypoechoic on USG also had a high probability to be malignant (PPV 92%). We recommend repeat FNA on AUS-1 nodules rather than proceeding directly to GEC testing. Also, we suggest that among AUS-2 nodules, surgery can be recommended when USG shows solid and hypoechoic features with GEC testing reserved for the remainder.

Keywords: Thyroid nodules; Thyroid cancer- clinical; Pathologythyroid cytology; Radiology-imaging

Select your language of interest to view the total content in your interested language

Post Your Comment
Share This Article
Article Usage
  • Total views: 8210
  • [From(publication date): 6-2016 - Dec 14, 2017]
  • Breakdown by view type
  • HTML page views: 8137
  • PDF downloads: 73